Abstract
Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Anthrax / immunology
-
Anthrax / microbiology
-
Anthrax / prevention & control
-
Anthrax Vaccines / administration & dosage*
-
Anthrax Vaccines / immunology
-
Antibodies, Bacterial / administration & dosage*
-
Antibodies, Bacterial / blood
-
Antibodies, Bacterial / immunology
-
Area Under Curve
-
Bacillus anthracis / immunology
-
Drug Antagonism
-
Female
-
Half-Life
-
Humans
-
Immunoglobulins, Intravenous / blood
-
Immunoglobulins, Intravenous / immunology
-
Immunoglobulins, Intravenous / pharmacokinetics*
-
Infusions, Intravenous
-
Male
-
Rabbits
-
Respiratory Tract Infections / immunology
-
Respiratory Tract Infections / microbiology
-
Respiratory Tract Infections / prevention & control
-
Vaccination
Substances
-
Anthrax Vaccines
-
Antibodies, Bacterial
-
Biothrax
-
Immunoglobulins, Intravenous